{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:03Z","timestamp":1789609083472,"version":"build-2803163510"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundamental Research Program of Shanxi Province","award":["202303021221132"],"award-info":[{"award-number":["202303021221132"]}]},{"name":"the Special Fund for Science and Technology Innovation Teams of Shanxi Province","award":["202304051001017"],"award-info":[{"award-number":["202304051001017"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72574132"],"award-info":[{"award-number":["72574132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72474125"],"award-info":[{"award-number":["72474125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer (CCA) remains a major cause of morbidity and mortality among women globally, particularly in low- and middle-income countries. Although human papillomavirus (HPV) vaccination is central to prevention, safety concerns may affect vaccine acceptance. We integrated global disease-burden trends with real-world post-marketing safety data to provide complementary public health evidence for CCA prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using Global Burden of Disease (GBD) 2021 data, we assessed global prevalence, incidence, death, and disability-adjusted life years (DALYs) for women with CCA from 1990\u20132021, and applied age\u2013period\u2013cohort (APC) models to characterize temporal patterns. Bayesian APC models were used to project future incidence and death, with retrospective validation. For vaccine safety, adverse event (AE) reports following HPV vaccination in females (Cervarix, Gardasil, Gardasil 9; 2006\u20132025) were extracted from the Vaccine Adverse Event Reporting System (VAERS). We performed disproportionality analyses using four algorithms to identify reporting signals, with designated medical event (DME) screening and subgroup analyses by age and vaccine type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Globally, the age-standardized incidence rate of CCA decreased from 18.1 to 15.3 cases per 100,000 women from 1990 to 2021, while new cases increased from 0.41 million to 0.67 million. The highest incidence and death rates were observed in sub-Saharan Africa and selected Pacific Island countries. Projections suggest continued declines in age-standardized incidence and death through 2050, although the absolute burden will likely remain substantial. In VAERS, 41,731 HPV vaccine-related reports were identified; most were non-serious (80.9%). Syncope (ROR\u2009=\u20095.81, 95%CI:5.64\u20135.99), loss of consciousness (ROR\u2009=\u20095.26, 95%CI: 5.06\u20135.47) and pallor (ROR\u2009=\u20096.39, 95%CI: 6.10\u20136.70) were the most frequently reported events, and six potential DME-related signals were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite declining age-standardized rates, CCA continues to impose a substantial global burden with marked regional disparities. Sustained HPV vaccine prevention efforts should be supported by epidemiological evidence and transparent, evidence-based safety communication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0345286","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:24:56Z","timestamp":1774286696000},"page":"e0345286","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Global trends and forecasts of cervical cancer and a real-world safety assessment of human papillomavirus vaccines in women: A systematic analysis of the Global Burden of Disease study 2021 and the Vaccine Adverse Event Reporting System database"],"prefix":"10.1371","volume":"21","author":[{"given":"Kai","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-6899","authenticated-orcid":true,"given":"Qi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"pone.0345286.ref001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"pone.0345286.ref002","doi-asserted-by":"crossref","first-page":"759928","DOI":"10.3389\/fmed.2022.759928","article-title":"Novel Insight of CircRNAs in Cervical Cancer: Potential Biomarkers and Therapeutic Target","volume":"9","author":"M Wu","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pone.0345286.ref003","first-page":"135","article-title":"Analysis and interpretation of the 2022 global cancer statistics report: cancer burden and epidemiological trends in China and the world","volume":"24","author":"Q Wu","year":"2025","journal-title":"Journal of Diagnostics Concepts & Practice"},{"key":"pone.0345286.ref004","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"B Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"pone.0345286.ref005","volume-title":"Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem","author":"World Health Organization","year":"2020"},{"issue":"1","key":"pone.0345286.ref006","first-page":"73","article-title":"Human Papillomavirus (HPV) and cervical cancer","volume":"68","author":"S Wardak","year":"2016","journal-title":"Med Dosw Mikrobiol"},{"issue":"23","key":"pone.0345286.ref007","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2017.04.060","article-title":"Mapping information exposure on social media to explain differences in HPV vaccine coverage in the United States","volume":"35","author":"AG Dunn","year":"2017","journal-title":"Vaccine"},{"key":"pone.0345286.ref008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ypmed.2018.11.005","article-title":"Stories about HPV vaccine in social media, traditional media, and conversations","volume":"118","author":"MA Margolis","year":"2019","journal-title":"Prev Med"},{"issue":"9","key":"pone.0345286.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(20)30139-0","article-title":"Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey","volume":"5","author":"K Sonawane","year":"2020","journal-title":"Lancet Public Health"},{"key":"pone.0345286.ref010","doi-asserted-by":"crossref","first-page":"1452916","DOI":"10.3389\/fcimb.2024.1452916","article-title":"Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant","volume":"14","author":"KT Miyaji","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"48","key":"pone.0345286.ref011","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1016\/j.vaccine.2023.10.041","article-title":"Comparison of the safety and persistence of immunogenicity of bivalent HPV16\/18 vaccine in healthy 9\u201314-year-old and 18\u201326-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial","volume":"41","author":"J Li","year":"2023","journal-title":"Vaccine"},{"issue":"9","key":"pone.0345286.ref012","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.vaccine.2024.02.085","article-title":"Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia","volume":"42","author":"I Maldonado","year":"2024","journal-title":"Vaccine"},{"key":"pone.0345286.ref013","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"pone.0345286.ref014","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"RT Chen","year":"1994","journal-title":"Vaccine"},{"key":"pone.0345286.ref015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03256752","article-title":"MedDRA: An overview of the medical dictionary for regulatory activities","volume":"23","author":"PJM Mozzicato","year":"2009","journal-title":"Pharm Med"},{"issue":"4","key":"pone.0345286.ref016","doi-asserted-by":"crossref","first-page":"106250","DOI":"10.1016\/j.jinf.2024.106250","article-title":"Global temporal trends and projections of acute hepatitis E incidence among women of childbearing age: Age-period-cohort analysis 2021","volume":"89","author":"D Huang","year":"2024","journal-title":"J Infect"},{"issue":"11","key":"pone.0345286.ref017","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1158\/1055-9965.EPI-14-0300","article-title":"A web tool for age-period-cohort analysis of cancer incidence and mortality rates","volume":"23","author":"PS Rosenberg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"26","key":"pone.0345286.ref018","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1002\/sim.6248","article-title":"A Bayesian generalized age-period-cohort power model for cancer projections","volume":"33","author":"V J\u00fcrgens","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"pone.0345286.ref019","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/jcm12041291","article-title":"The Burden of Rheumatoid Arthritis: Findings from the 2019 Global Burden of Diseases Study and Forecasts for 2030 by Bayesian Age-Period-Cohort Analysis","volume":"12","author":"Y Cai","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"pone.0345286.ref020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0345286.ref021","doi-asserted-by":"crossref","first-page":"1666509","DOI":"10.3389\/fcimb.2025.1666509","article-title":"Comparative safety evaluation of pentavalent (DTaP-IPV-Hib) and hexavalent (DTaP-IPV-Hib-HepB) vaccines in infants: a real-world analysis based on VAERS","volume":"15","author":"Z Wei","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"pone.0345286.ref022","unstructured":"European Medicines Agency. Signal management\u2014Designated medical events. [Cited 4\/12\/2025] https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/signal-management"},{"key":"pone.0345286.ref023","unstructured":"Google. Google trends. [Cited 2025 April 12]. https:\/\/trends.google.com\/trends\/"},{"issue":"3","key":"pone.0345286.ref024","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bcp.13841","article-title":"Safety profile of human papilloma virus vaccines: an analysis of the US vaccine adverse event reporting system from 2007 to 2017","volume":"85","author":"G Bonaldo","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0345286.ref025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"M Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci"},{"issue":"10","key":"pone.0345286.ref026","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"O Sauzet","year":"2013","journal-title":"Drug Saf"},{"issue":"3","key":"pone.0345286.ref027","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1055-9965.EPI-04-0569","article-title":"Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening","volume":"14","author":"F Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"pone.0345286.ref028","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ijc.32014","article-title":"Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012","volume":"144","author":"M Utada","year":"2019","journal-title":"Int J Cancer"},{"key":"pone.0345286.ref029","volume-title":"Immunization stress-related responses (ISRR): A manual for program managers and health professionals","author":"World Health Organization","year":"2019"},{"issue":"3","key":"pone.0345286.ref030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archpedi.1997.02170400041007","article-title":"Syncope after immunization","volume":"151","author":"MM Braun","year":"1997","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"17","key":"pone.0345286.ref031","first-page":"457","article-title":"Syncope after vaccination\u2014United States, January 2005\u2013July 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"pone.0345286.ref032","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"BA Slade","year":"2009","journal-title":"JAMA"},{"key":"pone.0345286.ref033","doi-asserted-by":"crossref","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019","volume":"144","author":"L Bruni","year":"2021","journal-title":"Prev Med"},{"issue":"4","key":"pone.0345286.ref034","doi-asserted-by":"crossref","first-page":"2324709614556129","DOI":"10.1177\/2324709614556129","article-title":"Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice","volume":"2","author":"DT Little","year":"2014","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"4","key":"pone.0345286.ref035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/aji.12151","article-title":"Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune\/inflammatory syndrome induced by adjuvants","volume":"70","author":"S Colafrancesco","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"pone.0345286.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/j.acap.2017.09.014","article-title":"Ten Years of Human Papillomavirus Vaccination in the United States","volume":"18","author":"LE Markowitz","year":"2018","journal-title":"Acad Pediatr"},{"issue":"49","key":"pone.0345286.ref037","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"E Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0345286.ref038","author":"PJLPHE England"},{"key":"pone.0345286.ref039","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.ypmed.2020.106335","article-title":"National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects","volume":"144","author":"VD Tsu","year":"2021","journal-title":"Prev Med"},{"key":"pone.0345286.ref040","unstructured":"World Health Organization. HPV vaccine included in national immunisation programme. [Cited 2025 April 13]. WHO PowerBI Dashboard. https:\/\/app.powerbi.com\/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9"},{"key":"pone.0345286.ref041","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.15585\/mmwr.mm6933a1","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2019","volume":"69","author":"LD Elam-Evans","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0345286.ref042","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2018.1564436","article-title":"HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe","volume":"15","author":"E Karafillakis","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"pone.0345286.ref043","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/08901171221091438","article-title":"Factors that Influence Healthcare Provider Recommendation of HPV vaccination","volume":"36","author":"R Btoush","year":"2022","journal-title":"Am J Health Promot"},{"key":"pone.0345286.ref044","doi-asserted-by":"crossref","first-page":"1203610","DOI":"10.3389\/fpubh.2023.1203610","article-title":"Frequency of health care provider recommendations for HPV vaccination: a survey in three large cities in China","volume":"11","author":"Y Mao","year":"2023","journal-title":"Front Public Health"},{"issue":"37","key":"pone.0345286.ref045","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.vaccine.2013.06.016","article-title":"Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects","volume":"31","author":"J Wigle","year":"2013","journal-title":"Vaccine"},{"issue":"17","key":"pone.0345286.ref046","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.vaccine.2021.03.049","article-title":"Parents\u2019 knowledge, beliefs, acceptance and uptake of the HPV vaccine in members of The Association of Southeast Asian Nations (ASEAN): A systematic review of quantitative and qualitative studies","volume":"39","author":"KE Wijayanti","year":"2021","journal-title":"Vaccine"},{"issue":"44","key":"pone.0345286.ref047","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1016\/j.vaccine.2011.07.107","article-title":"Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: a cross-sectional study","volume":"29","author":"L Jaspers","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"pone.0345286.ref048","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/LGT.0b013e3181865f44","article-title":"Preventing cervical cancer through human papillomavirus vaccination: perspective from focus groups","volume":"13","author":"LP Wong","year":"2009","journal-title":"J Low Genit Tract Dis"},{"key":"pone.0345286.ref049","author":"S Fox","year":"1999","journal-title":"The Online Health Care Revolution: How the Web Helps Americans Take Better Care of Themselves"},{"issue":"1","key":"pone.0345286.ref050","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41598-018-21912-x","article-title":"Factors influencing intention to obtain the HPV vaccine in South East Asian and Western Pacific regions: A systematic review and meta-analysis","volume":"8","author":"D Santhanes","year":"2018","journal-title":"Sci Rep"},{"issue":"7","key":"pone.0345286.ref051","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.vaccine.2009.11.079","article-title":"Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey","volume":"28","author":"J-K Oh","year":"2010","journal-title":"Vaccine"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:25:05Z","timestamp":1774286705000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345286"}},"subtitle":[],"editor":[{"given":"Laura","family":"Conde-Ferr\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345286","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}